Zymeworks Gaining on Positive Topline Trial Data Announcement

December 19, 2022

(24/7 MARKET NEWS) – Zymeworks Inc. (NASDAQ:ZYME) announced positive topline results, this morning, from its pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing BTC. zanidatamab is positioned to potentially become the first HER2-targeted therapy for patients with BTC, pending receipt of regulatory approvals.

Zymeworks is trading higher in this morning’s premarket, at $8.09, up $1.63 (+25.23%), on 170 thousand shares traded.

Its 52-week range is $4.11 to $17.27. If it can break through this morning’s premarket high, $9.31, on strong volume, it has a favorable setup for a potential run to near the $14 level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.